| abstract |
The invention relates in general to methods for determining the probability that a subject will quit tobacco consumption in response to pharmacological treatment with a nicotinic cholinergic receptor agonist drug, such as varenicline, said methods being based on an analysis of at least one allele of one or more of single-nucleotide polymorphisms (SNP) rs678188, rs9658498, rs4821566, rs10891510, rs11932367 and rs2023239, or any SNP of the corresponding linkage blocks thereof, in a sample from a subject, and optionally combined with clinical variables. |